Does Blue Cross Blue Shield of Michigan Cover Eliquis? A Woman's Complete Guide

What Is Eliquis and Why Do Women Get Prescribed It?

Eliquis (apixaban) is an oral direct factor Xa inhibitor approved by the FDA for five indications: reducing stroke risk in nonvalvular atrial fibrillation (AFib), treating and preventing recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and preventing DVT after hip or knee replacement surgery. It works by blocking factor Xa, a protein in the clotting cascade, without requiring routine INR monitoring the way warfarin does.

Women are not a minority of Eliquis users. Venous thromboembolism (VTE, meaning DVT and PE combined) affects approximately 900,000 Americans each year, and women face several sex-specific risk factors that men do not: hormonal contraception, pregnancy, the postpartum period, and hormone therapy in menopause. AFib prevalence also climbs steeply after menopause, so if you are in your 50s or 60s and recently diagnosed, Eliquis may be the drug your cardiologist or internist recommends.

Why Women Have Distinct Clotting Risks

Combined oral contraceptives containing estrogen raise VTE risk three- to fourfold compared with non-users. That risk stacks on top of any inherited thrombophilia you may carry, such as factor V Leiden or prothrombin gene mutation. Women who carry factor V Leiden and use estrogen-containing contraceptives face a VTE risk approximately 35 times higher than women with neither risk factor.

After menopause, declining estrogen shifts the lipid profile and vascular tone in ways that raise cardiovascular risk. Among postmenopausal women, AFib is the most common sustained cardiac arrhythmia, and the CHA2DS2-VASc score assigns one extra point simply for female sex, meaning many women reach the threshold for anticoagulation at a lower overall burden of other risk factors than men.

Indications Specific to Women

Beyond AFib and VTE, apixaban is occasionally used off-label or under investigation for:

• Antiphospholipid syndrome (APS), a condition that disproportionately affects women and is a major cause of recurrent pregnancy loss. Note: Direct oral anticoagulants including apixaban are generally not recommended over warfarin for obstetric APS based on current ACOG guidance.
• Post-COVID hypercoagulable states, which data suggest may be more symptomatic in younger women.
• Prophylaxis during prolonged immobility after pelvic or abdominal surgery, including gynecologic oncology procedures.

How Blue Cross Blue Shield of Michigan Covers Eliquis

BCBS Michigan operates as an independent licensee of the Blue Cross Blue Shield Association and administers multiple distinct plan types. Coverage for Eliquis depends on which plan you hold.

Commercial (Employer-Sponsored) Plans

On most BCBS Michigan commercial formularies, apixaban falls on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 cost-sharing typically runs $60 to $120 per 30-day fill after the deductible is met. Tier 4 can run $150 to $350 or more per fill depending on your plan's specific benefit design.

Prior authorization (PA) is required on the majority of commercial plans. BCBS Michigan's PA criteria for Eliquis generally require documentation that the prescribing clinician has established one of the FDA-approved indications, and in some plans, documentation that a trial of warfarin was considered or found inappropriate.

A practical framework for getting your PA approved faster:

1. Ask your prescriber to submit the PA at the time of the initial prescription, not after your first fill is denied.
2. Request that the PA letter include your specific indication (e.g., "new PE with high recurrence risk"), the reason warfarin is not preferred (e.g., "patient of childbearing potential with planned pregnancy monitoring complexity" or "labile INR history"), and any relevant lab results (d-dimer, imaging report).
3. If the PA is denied, ask for a peer-to-peer review between your prescriber and the BCBS Michigan medical director. This single step overturns a substantial proportion of initial PA denials.
4. If peer-to-peer fails, file a formal appeal. Under Michigan law, you have the right to an expedited appeal within 72 hours if your condition is urgent.

Medicare Advantage Plans

BCBS Michigan administers several Medicare Advantage (MA) products in the state. Under these plans, Eliquis is covered on Part D formularies, typically at the Tier 3 brand level. In 2025, the Inflation Reduction Act caps out-of-pocket drug costs for Medicare Part D enrollees, so your annual maximum exposure for Eliquis under a BCBS Michigan MA plan is capped at $2,000 for the 2025 plan year. For many postmenopausal women taking Eliquis long-term, this cap makes Medicare coverage more predictable than commercial coverage.

The Low Income Subsidy (Extra Help) program can reduce your Part D cost-sharing to a few dollars per fill. If your income is at or below 150% of the federal poverty level, ask your pharmacist or BCBS Michigan member services about Extra Help enrollment.

Marketplace (ACA Exchange) Plans

ACA plans sold through Michigan's exchange (healthcare.gov) use tiered formularies that mirror commercial plans. Bronze and silver plans may place Eliquis on a tier that puts your cost at 30% to 50% coinsurance after the deductible, which can mean $200 to $350 per fill in the deductible phase. Gold and platinum plans typically have lower cost-sharing for Tier 3 drugs. If you are shopping during open enrollment and know you need Eliquis, downloading the plan's specific formulary PDF before selecting a plan is time you will not regret spending.

Medicaid (Blue Cross Complete of Michigan)

Blue Cross Complete is BCBS Michigan's Medicaid managed care plan. Michigan Medicaid generally covers apixaban for Medicaid-eligible individuals, but the formulary is managed separately and may require PA with stricter criteria than commercial plans. Cost-sharing for Medicaid enrollees is minimal by statute.

What Eliquis Actually Costs in Michigan and How to Reduce It

The average retail price for apixaban 5 mg twice daily (the most common dose for AFib and VTE treatment) runs approximately $600 to $700 for a 30-day supply at major Michigan pharmacy chains as of mid-2025. A 2.5 mg twice daily regimen costs slightly less.

The Bristol-Myers Squibb/Pfizer Copay Card

For commercially insured patients who are not enrolled in a government program (Medicare, Medicaid, CHIP, TRICARE), the Eliquis copay card can reduce your monthly cost to as low as $10 for up to 24 months. You cannot use this card with Medicare or Medicaid plans, which is a common source of confusion when a woman transitions from commercial to Medicare at age 65.

Patient Assistance Programs

Bristol-Myers Squibb's patient assistance program, BMS Access Support, provides free Eliquis to uninsured or underinsured patients who meet income eligibility criteria. Applications are submitted through your prescriber's office or through BMS Access Support directly. Income thresholds change annually.

GoodRx and Cash-Pay Options

GoodRx and similar discount programs can bring the out-of-pocket price for apixaban to $400 to $550 at some Michigan pharmacies when you opt out of using your insurance. This strategy makes sense only if your deductible is very high and you are unlikely to meet it, because cash-pay purchases do not count toward your insurance deductible.

Pregnancy and Lactation Safety: What Every Woman Must Know

Eliquis is contraindicated in pregnancy. This is not a nuanced or contested point. Apixaban crosses the placenta, and factor Xa inhibitors are associated with fetal hemorrhage, pregnancy loss, and fetal abnormalities in animal studies. There are no adequate, well-controlled studies in pregnant humans, and the FDA label explicitly advises against use during pregnancy.

If you are of reproductive age and prescribed Eliquis, you need a reliable contraceptive method. This is not optional counseling. Your prescriber should discuss contraception at the time of prescribing. Combined hormonal contraception (pill, patch, ring) raises VTE risk on its own, so for a woman already anticoagulated for VTE, a progestin-only method (implant, hormonal IUD, progestin-only pill) or barrier method is the safer choice, though the specifics depend on your underlying indication and thrombophilia status.

If You Need Anticoagulation During Pregnancy

Women who need anticoagulation during pregnancy, including those with DVT, PE, mechanical heart valves, or antiphospholipid syndrome, should be managed with low-molecular-weight heparin (LMWH), most commonly enoxaparin. Warfarin is used in very specific circumstances (mechanical valves) but carries its own fetal risks in the first trimester. Direct oral anticoagulants including apixaban are not currently recommended in pregnancy by any major guideline body. ACOG Practice Bulletin 197 on thromboembolism in pregnancy addresses this in detail.

Lactation

Apixaban is present in breast milk in animal studies. Human lactation data are absent. The FDA label recommends that women not breastfeed while taking Eliquis, given the unknown risk of hemorrhagic complications in the nursing infant and the absence of safety data. If you are postpartum and need anticoagulation while breastfeeding, enoxaparin or warfarin (warfarin does not transfer meaningfully into breast milk) are the established alternatives.

Postpartum Clot Risk

The postpartum period carries the highest VTE risk of any phase of a woman's reproductive life. Risk peaks in the first six weeks after delivery and remains elevated for up to 12 weeks. A large cohort study published in JAMA found a 22-fold increase in VTE risk in the first six weeks postpartum compared with non-pregnant women. If you were diagnosed with a PE or DVT during or immediately after pregnancy and are now breastfeeding, discuss the anticoagulation transition plan explicitly with your OB and hematologist before switching to Eliquis.

Life Stage Guide: Who Is Most Likely to Be Prescribed Eliquis and What to Expect

Reproductive Years (Ages 18 to 40)

If you are under 40 and prescribed Eliquis, the most common scenarios are a provoked DVT or PE (often triggered by hormonal contraception, immobility, or surgery) or an inherited thrombophilia with a first clot event. The AMPLIFY trial, which enrolled 5,395 patients with acute VTE, showed apixaban was non-inferior to enoxaparin plus warfarin for initial treatment and had significantly less major bleeding. Women represented approximately 45% of the AMPLIFY cohort, though sex-stratified data were not a primary endpoint.

For treatment of a first provoked DVT, many guidelines support a finite course of 3 to 6 months. The question of stopping versus continuing is made together with your prescriber based on whether the provoking factor (e.g., the combined pill you stopped taking) has been permanently removed.

Contraception counseling is mandatory. You should not take combined hormonal contraception while on Eliquis for VTE, because the estrogen adds clotting risk on top of an already-vulnerable vascular system.

Perimenopause (Roughly Ages 45 to 55)

Perimenopausal women experience irregular cycles, fluctuating estrogen, and often trial different hormonal therapies. Several points deserve attention:

• Menometrorrhagia (heavy, irregular uterine bleeding) is already common in perimenopause. Adding an anticoagulant can significantly worsen abnormal uterine bleeding. The ARISTOTLE trial, the landmark AFib trial for apixaban (18,201 patients, approximately 35% women), noted that women had more bleeding events at baseline than men, though major bleeding rates with apixaban were still lower than with warfarin.
• If you start hormone therapy for menopause symptoms while on Eliquis, the type and route of hormone therapy matters. Transdermal estradiol carries a lower VTE risk than oral estrogen based on observational data from the E3N cohort study, though you are already anticoagulated if you are on Eliquis, so the interaction is complex and worth a dedicated conversation with your prescriber.
• Bone density begins to decline in perimenopause. Long-term anticoagulation with warfarin is associated with bone loss, but apixaban does not appear to carry the same risk based on current data, which is a meaningful advantage if you are already managing osteopenia.

Postmenopause (Ages 55 and Beyond)

This is the life stage where AFib diagnoses cluster in women. The lifetime risk of AFib is approximately 1 in 4 for adults over 40, and women with AFib have a higher stroke risk than men with AFib at comparable CHA2DS2-VASc scores, according to a meta-analysis of 30 studies published in Thrombosis and Haemostasis.

For postmenopausal women on Medicare, the 2025 Part D out-of-pocket cap at $2,000 is a genuine financial relief compared with the commercial tier system. Know your plan's tier and whether your specific BCBS Michigan Medicare Advantage plan covers Eliquis at the standard brand tier or has placed it on a higher tier this plan year, because formularies can change annually.

Renal function declines with age, and apixaban dosing for AFib requires a dose reduction to 2.5 mg twice daily if you meet two of three criteria: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Ask your prescriber whether your dose has been reviewed against your current kidney function labs.

"Does BCBS Michigan Cover Eliquis?" The Specific Steps to Find Out for Your Plan

The honest answer is: probably yes, but at a cost that requires active management. Here is how to confirm coverage for your specific plan:

1. Call the member services number on the back of your BCBS Michigan card and ask: "Is apixaban (Eliquis) on my formulary, what tier is it on, and does it require prior authorization?"
2. Ask for the formulary exception process if your plan does not cover Eliquis or places it on a non-preferred tier. Your prescriber can submit a formulary exception with medical justification.
3. Check the BCBS Michigan drug formulary tool online at bcbsm.com. Enter your plan name and search for "apixaban." The result will show tier, quantity limits, and PA requirements.
4. Request the PA criteria document so you and your prescriber know exactly what clinical information to include in the authorization request.

As WomanRx reviewer Elena Vasquez, MD, puts it: "Women prescribed Eliquis for the first time are often surprised by the PA process. The easiest thing your doctor can do is send a brief note documenting your exact indication and why warfarin is not preferred in your case. That single paragraph answers 80% of what the insurer is looking for."

Who This Is Right For and Who Should Pause

Eliquis may be the appropriate anticoagulant for you if:

• You have been diagnosed with nonvalvular AFib and your CHA2DS2-VASc score is 2 or higher (women reach this threshold at a lower burden of other risk factors because female sex itself contributes one point).
• You have experienced a DVT or PE and your prescriber recommends a direct oral anticoagulant rather than warfarin because of monitoring burden or labile INR history.
• You have had hip or knee replacement surgery and need short-term VTE prophylaxis.
• You have an indication where routine INR monitoring is impractical.

Eliquis is not the right choice if:

• You are pregnant or actively trying to conceive without a clear plan to transition to LMWH before conception.
• You have significant kidney disease (creatinine clearance below 25 mL/min). The FDA label notes that patients with this level of renal impairment were excluded from major trials.
• You have antiphospholipid syndrome, particularly triple-positive APS. The TRAPS trial showed rivaroxaban (a related drug) was significantly inferior to warfarin in triple-positive APS patients, and expert consensus now extends this caution to all direct oral anticoagulants in this population. ACOG and the American College of Rheumatology both recommend warfarin as first-line for thrombotic APS.
• You are breastfeeding and cannot use enoxaparin or warfarin as alternatives.

Evidence Gaps in Women: What We Know and What We Do Not

Women have historically been under-represented in the large anticoagulation trials. In ARISTOTLE, 35% of participants were women. In AMPLIFY, approximately 45% were women. Neither trial was powered to detect sex-specific differences in efficacy or bleeding outcomes as a primary endpoint. This matters because:

• Women's lower average body weight may affect drug exposure differently than in men, since apixaban pharmacokinetics are influenced by body weight.
• Women have higher baseline fibrinogen levels and different platelet reactivity, which may modify the drug's anticoagulant effect in ways the trials were not designed to capture.
• Menstrual blood loss on apixaban is not well characterized in published literature. Anecdotal reports of heavier periods are common in clinical practice, but prospective data are thin. If you notice significant changes to your menstrual pattern after starting Eliquis, report this to your prescriber. It is a clinically meaningful bleeding event, not a minor side effect.

A sex-disaggregated analysis of ARISTOTLE published in the Journal of the American College of Cardiology found that the relative reduction in stroke risk with apixaban versus warfarin was consistent between women and men, and major bleeding risk was lower with apixaban in both sexes. This is reassuring, though it does not resolve the questions about menstrual bleeding, reproductive-age pharmacokinetics, or drug interactions with hormonal therapies.